Free Trial
CVE:MPH

Medicure 4/8/2024 Earnings Report

Medicure logo
C$1.06 +0.12 (+12.77%)
As of 05/28/2025 10:09 AM Eastern

Medicure EPS Results

Actual EPS
-C$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$5.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Medicure Earnings Headlines

Shocking discovery could help you target payouts on weekends…
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
Medicure Inc. (NGQ1.F)
Medicure Inc. (MPH.V)
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (CVE:MPH), a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

View Medicure Profile

More Earnings Resources from MarketBeat